Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Prokidney (PROK) over the last 3 years, with Sep 2025 value amounting to $32.3 million.

  • Prokidney's Total Non-Current Liabilities rose 5.74% to $32.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year increase of 5.74%. This contributed to the annual value of $38.7 million for FY2024, which is 35.05% up from last year.
  • Latest data reveals that Prokidney reported Total Non-Current Liabilities of $32.3 million as of Q3 2025, which was up 1.67% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Prokidney's Total Non-Current Liabilities registered a high of $38.7 million during Q4 2024, and its lowest value of $11.6 million during Q3 2022.
  • Its 3-year average for Total Non-Current Liabilities is $28.3 million, with a median of $28.6 million in 2023.
  • Per our database at Business Quant, Prokidney's Total Non-Current Liabilities skyrocketed by 124.18% in 2023 and then dropped by 2.07% in 2024.
  • Prokidney's Total Non-Current Liabilities (Quarterly) stood at $12.8 million in 2022, then spiked by 124.18% to $28.6 million in 2023, then surged by 35.05% to $38.7 million in 2024, then increased by 5.74% to $32.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $32.3 million for Q3 2025, versus $31.8 million for Q2 2025 and $35.3 million for Q1 2025.